Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS

12

Nov 2025

LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS

LabVantage Solutions, Inc., a global provider of laboratory informatics solutions and services, today announced it has been awarded a contract by the U.S. Department of Homeland Security's Customs and Border Protection (CBP) valued at up to $22.3 million over ten years. The agreement supports modernization of the agency's Forensic Laboratory Information Management System (FLIMS) to advance scientific and forensic operations that underpin U.S. border security and trade enforcement.

LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS

12

Nov 2025

LabVantage Solutions awarded $22.3 million U.S. customs and border protection contract to deliver next-generation forensic LIMS

LabVantage Solutions, Inc., a global provider of laboratory informatics solutions and services, today announced it has been awarded a contract by the U.S. Department of Homeland Security's Customs and Border Protection (CBP) valued at up to $22.3 million over ten years. The agreement supports modernization of the agency's Forensic Laboratory Information Management System (FLIMS) to advance scientific and forensic operations that underpin U.S. border security and trade enforcement.

Common antibiotic can improve survival and neurological outcomes in CNS-TB

12

Nov 2025

Common antibiotic can improve survival and neurological outcomes in CNS-TB

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study.

Common antibiotic can improve survival and neurological outcomes in CNS-TB

12

Nov 2025

Common antibiotic can improve survival and neurological outcomes in CNS-TB

Researchers at the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine), have demonstrated that doxycycline, a commonly available and inexpensive antibiotic, can improve survival rates and neurological outcomes in Central Nervous System Tuberculosis (CNS-TB) in a preclinical non-human study.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.